Important Class Action Notice for Shareholders of Applied Therapeutics, Inc. (APLT)

Urgent Notice to Shareholders of Applied Therapeutics, Inc. (APLT)

The Gross Law Firm has issued an important notification for shareholders of Applied Therapeutics, Inc., whose stock is traded on NASDAQ under the ticker APLT. This notice comes in light of a class action lawsuit that has been initiated regarding the drastic declines in the company’s stock value after certain critical announcements from the management.

If you purchased shares of Applied Therapeutics, Inc. during the specific class period, which spans from January 3, 2024, to December 2, 2024, it is highly encouraged that you reach out to the law firm. Engaging with this class action may enable you to recover potential losses resulting from the company’s actions and disclosures during this timeframe.

What Happened?

On November 27, 2024, Applied Therapeutics publicly issued a press release revealing they had received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for govorestat, the firm’s leading drug candidate. The contents of the CRL highlighted deficiencies in the submitted clinical data, effectively halting the approval process in its current form.

This announcement triggered a significant reaction in the stock market, with the share price plummeting from a closing price of $10.21 per share on November 26, 2024 to a low of $2.03 per share by November 29, 2024. This represented a jaw-dropping decline of over 80% in a matter of days. Moreover, on December 2, 2024, Applied Therapeutics revealed that they had received a